Mike Detke, M.D., Ph.D., is a board-certified psychiatrist and seasoned drug development executive with over 25 years of experience across biotech, pharma, and clinical research. He is the founder and president of Detke Biopharma Consulting LLC, where he advises pharma, biotech, and the NIH on CNS drug development and business strategy. Detke has held CMO roles at Cortexyme, Lighthouse, Embera NeuroTherapeutics, CoMentis, and MedAvante, and served as executive director for neuroscience at Eli Lilly, where he led global development for Cymbalta and Prozac.
He holds degrees from Yale and the University of Pennsylvania and completed his psychiatry residency at Harvard/MGH/McLean. Since 2000, he has been an adjunct clinical professor of psychiatry at Indiana University. Detke has authored over 70 peer-reviewed publications and is an active member of ACNP, ASCP, ISCTM, and SOBP. His expertise spans early through late-phase CNS development, regulatory strategy, and improving signal detection in clinical trials.
